Budget Amount *help |
¥5,330,000 (Direct Cost: ¥4,100,000、Indirect Cost: ¥1,230,000)
Fiscal Year 2014: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2013: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2012: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
|
Outline of Final Research Achievements |
Antimicrobial peptides are host defense peptides with a broad spectrum of microbicidal activity. In this study, we suggested that combined use of hBD3 and SP-A-derived peptide (SAP01) is a candidate as a therapeutic reagent against infectious diseases. Binding of SAP01 to hBD3 attenuated cytotoxicity and excess inflammation induced by hBD3. Interestingly, SAP01 did not affect microbicidal activity at concentration sufficient for anti-cytotoxic activity. Because hBD3 also effectively kill drug-resistant microbes, there is appreciable interest in hBD3 for pharmaceutical applications.
|